EX 10-19


                              INVESTMENT AGREEMENT

INVESTMENT AGREEMENT (this "AGREEMENT"), dated as of June 20, 2004 by and
between Human BioSystems, a California corporation (the "Company"), and Dutchess
Private Equities Fund, II, L.P., a Delaware limited partnership (the
"Investor").

Whereas, the parties desire that, upon the terms and subject to the conditions
contained herein, the Investor shall invest up to Five Million Dollars
($5,000,000) to purchase the Company's Common Stock, no par value per share (the
"Common Stock");

Whereas, such investments will be made in reliance upon the provisions of
Section 4(2) under the Securities Act of 1933, as amended (the "1933 Act"), Rule
506 of Regulation D, and the rules and regulations promulgated thereunder,
and/or upon such other exemption from the registration requirements of the 1933
Act as may be available with respect to any or all of the investments in Common
Stock to be made hereunder; and

Whereas, contemporaneously with the execution and delivery of this Agreement,
the parties hereto are executing and delivering a Registration Rights Agreement
substantially in the form attached hereto as Exhibit A (as amended from time to
time, the "Registration Rights Agreement") pursuant to which the Company has
agreed to provide certain registration rights under the 1933 Act, and the rules
and regulations promulgated thereunder, and applicable state securities laws.

NOW THEREFORE, in consideration of the foregoing recitals, which shall be
considered an integral part of this Agreement, the covenants and agreements set
forth hereafter, and other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the Company and the Investor hereby
agree as follows:

Section 1.  DEFINITIONS.

As used in this Agreement, the following terms shall have the following meanings
specified or indicated below, and such meanings shall be equally applicable to
the singular and plural forms of such defined terms.

"1933 Act" shall have the meaning set forth in the preamble, above.

"1934 Act" shall mean the Securities Exchange Act of 1934, as it may be amended.

"Affiliate" shall have the meaning specified in Section 5(h), below.

"Agreement" shall mean this Investment Agreement.

"Best Bid"  shall mean the highest posted bid price of the Common Stock.

"Buy In" shall have the meaning specified in Section 6, below.

"Buy In Adjustment Amount" shall have the meaning specified in Section 6.

"Closing" shall have the meaning specified in Section 2(h).

"Closing Date" shall mean the date which is no later than seven (7) Trading Days
following the Put Notice Date.

"Common Stock" shall have the meaning set forth in the preamble to this
Agreement.

"Control" or "Controls" shall have the meaning specified in Section 5(h).

"Covering Shares" shall have the meaning specified in Section 6.

"Effective Date" shall mean the date the SEC declares effective under the 1933
Act the Registration Statement covering the Securities.

"Environmental Laws" shall have the meaning specified in Section 4(m).

"Execution Date" shall mean the date indicated in the preamble to this
Agreement.

"Indemnities" shall have the meaning specified in Section 11.

"Indemnified Liabilities" shall have the meaning specified in Section 11.

"Ineffective Period" shall mean any period of time that the Registration
Statement  becomes ineffective or unavailable for use for the sale or resale, as
applicable, of any or all of the Registrable Securities (as defined in the
Registration Rights Agreement) for any reason (or in the event the prospectus
under either of the above is not current and deliverable) during any time period
required under the Registration Rights Agreement.

"Investor" shall have the meaning indicated in the preamble of this Agreement.

"Material Adverse Effect" shall have the meaning specified in Section 4(a).

"Maximum Common Stock Issuance" shall have the meaning specified in Section
2(i).

"Minimum Acceptable Price" with respect to any Put Notice Date shall mean 75% of
the average closing bid price for the ten Trading Day period immediately
preceding such Put Notice Date.

"Open Period" shall mean the period beginning on and including the Trading Day
immediately following the Effective Date and ending on the earlier to occur of
(i) the date which is thirty six (36) months from the Effective Date; or (ii)
termination of the Agreement in accordance with Section 9, below.

"Pricing Period" shall mean the period beginning on the Put Notice Date and
ending on and including the date that is five (5) consecutiveTrading Days after
such Put Notice Date.

"Principal Market" shall mean the American Stock Exchange, Inc., the National
Association of Securities Dealers, Inc. Over-the-Counter Bulletin Board, the
Nasdaq National Market System or the Nasdaq SmallCap Market, whichever is the
principal market on which the Common Stock is listed.

"Prospectus" shall mean the prospectus, preliminary prospectus and supplemental
prospectus used in connection with the Registration Statement.

"Purchase Amount" shall mean the total amount being paid by the Investor on a
particular Closing Date to purchase the Securities.

"Purchase Price" shall mean ninety-five percent (95%) of the lowest closing Best
Bid price of the Common Stock during the Pricing Period.

"Put Amount" shall have the meaning set forth in Section 2(b) hereof.

"Put Notice" shall mean a written notice sent to the Investor by the Company
stating the Put Amount of Shares the Company intends to sell to the Investor
pursuant to the terms of the Agreement and stating the current number of Shares
issued and outstanding on such date.

"Put Notice Date" shall mean the Trading Day immediately following the day on
which the Investor receives a Put Notice, however a Put Notice shall be deemed
delivered on (x) the Trading Day it is received by facsimile or otherwise by the
Investor if such notice is received prior to 9:00 am Eastern Time, or (y) the
immediately succeeding Trading Day if it is received by facsimile or otherwise
after 9:00 am Eastern Time on a Trading Day.  No Put Notice may be deemed
delivered on a day that is not a Trading Day.

"Put Restriction" shall mean the days between the end of the Pricing Period and
the Closing Date.  During this time, the Company shall not be entitled to
deliver another Put Notice.

"Registration Period" shall have the meaning specified in Section 5(c), below.

"Registration Rights Agreement" shall have the meaning set forth in the
recitals, above.

"Registration Statement" means the registration statement of the Company filed
under the 1933 Act covering the Common Stock issuable hereunder.

"Related Party" shall have the meaning specified in Section 5(h).

"Resolution" shall have the meaning specified in Section 8(e).

"SEC" shall mean the U.S. Securities & Exchange Commission.

"SEC Documents" shall have the meaning specified in Section 4(f).

"Securities" shall mean the shares of Common Stock issued pursuant to the terms
of the Agreement.

"Shares" shall mean the shares of the Company's Common Stock.

"Sold Shares" shall have the meaning specified in Section 6.

"Subsidiaries" shall mean the subsidiaries of the Company listed in Schedule
4(a).

"Trading Day" shall mean any day on which the Principal Market for the Common
Stock is open for trading, from the hours of 9:30 am until 4:00 pm Eastern Time.

"Transaction Documents" shall mean this Agreement, the Registration Rights
Agreement, and each of the other agreements entered into by the parties hereto
in connection with this Agreement.


Section 2.  PURCHASE AND SALE OF COMMON STOCK.

 (a)  Purchase and Sale of Common Stock.  Subject to the terms and conditions
 set forth herein, the Company shall issue and sell to the Investor, and the
 Investor shall purchase from the Company, up to that number of Shares having an
 aggregate Purchase Price of Five Million Dollars ($5,000,000).

 (b)  Delivery of Put Notices.

      (i)  Subject to the terms and conditions of the Transaction Documents, and
           from time to time during the Open Period, the Company may, in its
           sole discretion, deliver a Put Notice to the Investor which states
           the Put Amount which the Company intends to sell to the Investor on a
           Closing Date.  The Put Notice shall be in the form attached hereto as
           Exhibit B and incorporated herein by reference.  The amount that the
           Company shall be entitled to Put to the Investor in any single Put
           Notice (the "Put Amount") shall be equal to, at the Company's
           election, either: (a) two hundred percent (200%) of the average daily
           volume (U.S. market only) of the Common Stock for the ten (10)
           Trading Days prior to the applicable Put Notice Date, multiplied by
           the average of the three (3) daily closing Best Bid prices
           immediately preceding the Put Date, or (b) ten thousand $10,000.
           During the Open Period, the Company shall not be entitled to submit a
           Put Notice until after the previous Closing has been completed. The
           Purchase Price for the Common Stock identified in the Put Notice
           shall be equal to 95% of the lowest closing Best Bid price of the
           Common Stock during the Pricing Period.

     (ii)  If any closing bid price during the applicable Pricing Period with
           respect to that Put Notice is less than the Minimum Acceptable Price,
           the Put Notice will terminate at the Company's request.   In the
           event that the closing bid price for the applicable Pricing Period is
           less than the Minimum Acceptable Price, the Company may elect, by
           sending written notice to the Investor to cancel the Put Notice.

(c)  Reserved

(d)  Investor's Obligation to Purchase Shares.  Subject to the conditions set
forth in this Agreement, following the Investor's receipt of a validly delivered
Put Notice, the Investor shall be required to purchase from the Company during
the related Pricing Period that number of Shares having an aggregate Purchase
Price equal to the lesser of (i) the Put Amount set forth in the Put Notice, and
(ii) 20% of the aggregate trading volume of the Common Stock during the
applicable Pricing Period times (x) 95% of the lowest closing bid prices of the
Company's Common Stock during the specified Pricing Period, but only if said
Shares bear no restrictive legend, are not subject to stop transfer
instructions, pursuant to Section 2(h), prior to the applicable Closing Date.

(e)  Limitation on Investor's Obligation to Purchase Shares.  In no event shall
the Investor purchase Shares (whether from the Company or in public or private
secondary transactions) other than pursuant to this Agreement until such date as
this Agreement is terminated.

(f)  Conditions to Investor's Obligation to Purchase Shares. Notwithstanding
anything to the contrary in this Agreement, the Company shall not be entitled to
deliver a Put Notice and the Investor shall not be obligated to purchase any
Shares at a Closing (as defined in Section 2(h)) unless each of the following
conditions are satisfied:

     (i) a Registration Statement shall have been declared effective and shall
         remain effective and available for the resale of all the Registrable
         Securities (as defined in the Registration Rights Agreement) at all
         times until the Closing with respect to the subject Put Notice;

    (ii) at all times during the period beginning on the related Put Notice Date
         and ending on and including the related Closing Date, the Common Stock
         shall have been listed on the Principal Market and shall not have been
         suspended from trading thereon for a period of one consecutive Trading
         Day during the Open Period or one day during a Pricing Period, and the
         Company shall not have been notified of any pending or threatened
         proceeding or other action to de-list or suspend the Common Stock;

   (iii)the Company has complied with its obligations and is otherwise not in
        breach of a material provision of, or in default under, this Agreement,
        the Registration Rights Agreement or any other agreement executed in
        connection herewith which has not been corrected prior to delivery of
        the Put Notice Date;

   (iv) no injunction shall have been issued and remain in force, or action
        commenced by a governmental authority which has not been stayed or
        abandoned, prohibiting the purchase or the issuance of the Securities;
        and

   (v) the issuance of the Securities will not violate any shareholder approval
       requirements of the Principal Market.

If any of the events described in clauses (i) through (v) above occurs during a
Pricing Period, then the Investor shall have no obligation to purchase the Put
Amount of Common Stock set forth in the applicable Put Notice.

(g)  Reserved

(h)  Mechanics of Purchase of Shares by Investor.  Subject to the satisfaction
of the conditions set forth in Sections 2(f), 7 and 8, the closing of the
purchase by the Investor of Shares (a "Closing") shall occur on the date which
is no later than seven Trading Days following the applicable Put Notice Date
(each a "Closing Date").  Prior to each Closing Date, (i) the Company shall
deliver to the Investor pursuant to the this Agreement, certificates
representing the Shares to be issued to the Investor on such date and registered
in the name of the Investor; and (ii) the Investor shall deliver to the Company
the Purchase Price to be paid for such Shares, determined as set forth in
accordance with the terms of this Agreement. The company shall use a nationally
recognized overnight delivery (and provide a tracking number for package)service
to deliver the certificates to the address listed on the Put settlement sheet.
In lieu of delivering physical certificates representing the Securities and
provided that the Company's transfer agent then is participating in The
Depository Trust Company ("DTC") Fast Automated Securities Transfer ("FAST")
program, upon request of the Investor, the Company shall use its commercially
reasonable efforts to cause its transfer agent to electronically transmit the
Securities by crediting the account of the Investor's prime broker (which shall
be specified by the Investor a reasonably sufficient time in advance) with DTC
through its Deposit Withdrawal Agent Commission ("DWAC") system.

The Company understands that a delay in the issuance of Securities beyond the
Closing Date could result in economic loss to the Investor.  After the Effective
Date, as compensation to the Investor for such loss, the Company agrees to pay
late payments to the Investor for late issuance of Securities (delivery of
Securities after the applicable Closing Date) in accordance with the following
schedule (where "No. of Days Late" is defined as the number of days beyond the
Closing Date):

Late Payment For Each
No. of Days Late                        $10,000 of Common Stock

                1                                       $100
                2                                       $200
                3                                       $300
                4                                       $400
                5                                       $500
                6                                       $600
                7                                       $700
                8                                       $800
                9                                       $900
                10                                      $1,000
                Over 10                         $1,000 + $200 for each
                                                Business Day late beyond 10 days

The Company shall pay any payments incurred under this Section in immediately
available funds upon demand.  Nothing herein shall limit the Investor's right to
pursue actual damages for the Company's failure to issue and deliver the
Securities to the Investor, except to the extent that such late payments shall
constitute payment for and offset any such actual damages alleged by the
Investor, and any Buy In Adjustment Amount.

(i)  Overall Limit on Common Stock Issuable. Notwithstanding anything contained
herein to the contrary, if during the Open Period the Company becomes listed on
an exchange that limits the number of shares of Common Stock that may be issued
without shareholder approval, then the number of Shares issuable by the Company
and purchasable by the Investor,  shall not exceed that number of the shares of
Common Stock that may be issuable without shareholder approval, subject to
appropriate adjustment for stock splits, stock dividends, combinations or other
similar recapitalization affecting the Common Stock (the "Maximum Common Stock
Issuance"), unless the issuance of Shares, in excess of the Maximum Common Stock
Issuance shall first be approved by the Company's shareholders in accordance
with applicable law and the By-laws and Articles of Incorporation of the
Company, if such issuance of shares of Common Stock could cause a delisting on
the Principal Market. The parties understand and agree that the Company's
failure to seek or obtain such shareholder approval shall in no way adversely
affect the validity and due authorization of the issuance and sale of Securities
or the Investor's obligation in accordance with the terms and conditions hereof
to purchase a number of Shares in the aggregate up to the Maximum Common Stock
Issuance limitation, and that such approval pertains only to the applicability
of the Maximum Common Stock Issuance limitation provided in this Section 2(i).



Section 3.  INVESTOR'S REPRESENTATIONS, WARRANTIES AND COVENANTS.

        The Investor represents and warrants to the Company, and covenants,
        that:

        (a)   Sophisticated Investor.  The Investor has, by reason of its
        business and financial experience, such knowledge, sophistication and
        experience in financial and business matters and in making investment
        decisions of this type that it is capable of (i) evaluating the merits
        and risks of an investment in the Securities and making an informed
        investment decision; (ii) protecting its own interest; and (iii) bearing
        the economic risk of such investment for an indefinite period of time.

        (b)  Authorization; Enforcement.  This Agreement has been duly and
        validly authorized, executed and delivered on behalf of the Investor and
        is a valid and binding agreement of the Investor enforceable against the
        Investor in accordance with its terms, subject as to enforceability to
        general principles of equity and to applicable bankruptcy, insolvency,
        reorganization, moratorium, liquidation and other similar laws relating
        to, or affecting generally, the enforcement of applicable creditors'
        rights and remedies.

        (c)  Section 9 of the 1934 Act.  During the term of this Agreement, the
        Investor will comply with the provisions of Section 9 of the 1934 Act,
        and the rules promulgated thereunder, with respect to transactions
        involving the Common Stock.   The Investor agrees not to short, either
        directly or indirectly through its affiliates, principals or advisors,
        the Company's common stock during the term of this Agreement.

        (d)  Accredited Investor.  Investor is an "Accredited Investor" as that
        term is defined in Rule 501(a)(3) of Regulation D of the 1933 Act.

        (e)  No Conflicts.  The execution, delivery and performance of the
        Transaction Documents by the Investor and the consummation by the
        Investor of the transactions contemplated hereby and thereby will not
        result in a violation of the Partnership Agreement or other
        organizational documents of the Investor.

        (f)   Opportunity to Discuss.  The Investor has had an opportunity to
        discuss the business, management and financial affairs of the Company
        with the Company's management to a level satisfactory for this type of
        investment.

        (g)  Investment Purposes.  The Investor is purchasing the Securities for
        its own account for investment purposes and not with a view towards
        distribution and agrees to resell or otherwise dispose of the Securities
        solely in accordance with the registration provisions of the 1933 Act
        (or pursuant to an exemption from such registration provisions).

        (h)  No Registration as a Broker or Dealer.  The Investor is not and
        will not be required to be registered as a "broker or "dealer" under the
        1934 Act, either as a result of its execution and performance of its
        obligations under this Agreement or otherwise.

        (i)  Good Standing.  The Investor is a Limited Partnership, duly
        organized, validly existing and in good standing in the State of
        Delaware.

        (j)     Tax Liabilities.  The Investor understands that it is liable for
        its own tax liabilities.

        (k)  Regulation M.  The Investor will comply with Regulation M under the
        1934 Act, if applicable

Section 4.  REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

Except as set forth in the Schedules attached hereto, or as disclosed in the
Company's SEC Documents, the Company represents and warrants to the Investor
that:

(a)  Organization and Qualification.  The Company is a corporation duly
organized and validly existing in good standing under the laws of the State of
California, and has the requisite corporate power and authorization to own its
properties and to carry on its business as now being conducted. Each of the
Company and its Subsidiaries is duly qualified as a foreign corporation to do
business and is in good standing in every jurisdiction in which its ownership of
property or the nature of the business conducted by it makes such qualification
necessary, except to the extent that the failure to be so qualified or be in
good standing would not have a Material Adverse Effect. As used in this
Agreement, "Material Adverse Effect" means any material adverse effect on the
business, properties, assets, operations, results of operations, financial
condition or prospects of the Company and its Subsidiaries, if any, taken as a
whole, or on the transactions contemplated hereby or by the agreements and
instruments to be entered into in connection herewith, or on the authority or
ability of the Company to perform its obligations under the Transaction
Documents (as defined in Section 1 and 4(b), below).

(b)  Authorization; Enforcement; Compliance with Other Instruments.

     (i)  The Company has the requisite corporate power and authority to enter
     into and perform this Agreement, the Registration Rights Agreement, and
     each of the other agreements entered into by the parties hereto in
     connection with the transactions contemplated by this Agreement
     (collectively, the "Transaction Documents"), and to issue the Securities in
     accordance with the terms hereof and thereof.

    (ii) The execution and delivery of the Transaction Documents by the Company
    and the consummation by it of the transactions contemplated hereby and
    thereby, including without limitation the reservation for issuance and the
    issuance of the Securities pursuant to this Agreement, have been duly and
    validly authorized by the Company's Board of Directors and no further
    consent or authorization is required by the Company, its Board of Directors,
    or its shareholders.

   (iii) The Transaction Documents have been duly and validly executed and
   delivered by the Company.

   (iv)  The Transaction Documents constitute the valid and binding obligations
   of the Company enforceable against the Company in accordance with their
   terms, except as such enforceability may be limited by general principles of
   equity or applicable bankruptcy, insolvency, reorganization, moratorium,
   liquidation or similar laws relating to, or affecting generally, the
   enforcement of creditors' rights and remedies.

(c) Capitalization.  As of the date hereof, the authorized capital stock of the
Company consists of (i) 145,000,000 shares of Common Stock, no par value per
share, of which as of the date hereof, 36,468,600 shares are issued and
outstanding; (ii)  5,000,000 shares of Preferred Stock, no par value per share
authorized, with no shares issued or outstanding; and (iii) as of March 31,
2004, an aggregate of ____________ shares of common stock reserved for issuance
pursuant to options, warrants and other convertible securities.  All of such
outstanding shares have been, or upon issuance in accordance with the terms of
such options, warrants and other convertible securities will be, validly issued,
fully paid and nonassessable.  Except as disclosed in the Schedules or the
Company's SEC Documents, (i) no shares of the Company's capital stock are
subject to preemptive rights or any other similar rights or any liens or
encumbrances suffered or permitted by the Company; (ii) there are no outstanding
debt securities; (iii) there are no outstanding shares of capital stock,
options, warrants, scrip, rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities or rights convertible into, any
shares of capital stock of the Company or any of its Subsidiaries, or contracts,
commitments, understandings or arrangements by which the Company or any of its
Subsidiaries is or may become bound to issue additional shares of capital stock
of the Company or any of its Subsidiaries or options, warrants, scrip, rights to
subscribe to, calls or commitments of any character whatsoever relating to, or
securities or rights convertible into, any shares of capital stock of the
Company or any of its Subsidiaries; (iv) there are no agreements or arrangements
under which the Company or any of its Subsidiaries is obligated to register the
sale of any of their securities under the 1933 Act (except the Registration
Rights Agreement); (v) there are no outstanding securities of the Company or any
of its Subsidiaries which contain any redemption or similar provisions, and
there are no contracts, commitments, understandings or arrangements by which the
Company or any of its Subsidiaries is or may become bound to redeem a security
of the Company or any of its Subsidiaries; (vi) there are no securities or
instruments containing anti-dilution or similar provisions that will be
triggered by the issuance of the Securities as described in this Agreement;
(vii) the Company does not have any stock appreciation rights or "phantom stock"
plans or agreements or any similar plan or agreement; and (viii) there is no
dispute as to the classification of any shares of the Company's capital stock.
The Company has furnished to the Investor, or the Investor has had access
through EDGAR to, true and correct copies of the Company's Articles of
Incorporation, as in effect on the date hereof (the "Articles of
Incorporation"), and the Company's By-laws, as in effect on the date hereof (the
"By-laws"), and the terms of all securities convertible into or exercisable for
Common Stock and the material rights of the holders thereof in respect thereto.

(d)  Issuance of Shares.  The Company has reserved ___________ Shares for
issuance pursuant to this Agreement. Upon issuance in accordance with this
Agreement, the Shares will be validly issued, fully paid and non-assessable and
free from all taxes, liens and charges with respect to the issue thereof. In the
event the Company cannot register a sufficient number of Shares for issuance
pursuant to this Agreement, the Company will use its best efforts to authorize
and reserve for issuance the number of Shares required for the Company to
perform its obligations hereunder as soon as reasonably practicable.

(e)  No Conflicts.  The execution, delivery and performance of the Transaction
Documents by the Company and the consummation by the Company of the transactions
contemplated hereby and thereby will not (i) result in a violation of the
Articles of Incorporation, any Certificate of Designations, Preferences and
Rights of any outstanding series of preferred stock of the Company or the By-
laws; or (ii) conflict with, or constitute a material default (or an event which
with notice or lapse of time or both would become a material default) under, or
give to others any rights of termination, amendment, acceleration or
cancellation of, any material agreement, contract, indenture mortgage,
indebtedness or instrument to which the Company or any of its Subsidiaries is a
party, or result in a violation of any law, rule, regulation, order, judgment or
decree (including United States federal and state securities laws and
regulations and the rules and regulations of the Principal Market or principal
securities exchange or trading market on which the Common Stock is traded or
listed) applicable to the Company or any of its Subsidiaries or by which any
property or asset of the Company or any of its Subsidiaries is bound or
affected. Except as disclosed in Schedule 4(e), neither the Company nor its
Subsidiaries is in violation of any term of, or in default under, the Articles
of Incorporation, any Certificate of Designations, Preferences and Rights of any
outstanding series of preferred stock of the Company or the By-laws or their
organizational charter or by-laws, respectively, or any contract, agreement,
mortgage, indebtedness, indenture, instrument, judgment, decree or order or any
statute, rule or regulation applicable to the Company or its Subsidiaries,
except for possible conflicts, defaults, terminations, amendments,
accelerations, cancellations and violations that would not individually or in
the aggregate have a Material Adverse Effect. The business of the Company and
its Subsidiaries is not being conducted in violation of any law, statute,
ordinance, rule, order or regulation of any governmental authority or agency,
regulatory or self-regulatory agency, or court, except for possible violations
the sanctions for which either individually or in the aggregate would not have a
Material Adverse Effect.  Except as specifically contemplated by this Agreement
and as required under the 1933 Act, the Company is not required to obtain any
consent, authorization, permit or order of, or make any filing or registration
(except the filing of a registration statement) with, any court, governmental
authority or agency, regulatory or self-regulatory agency or other third party
in order for it to execute, deliver or perform any of its obligations under, or
contemplated by, the Transaction Documents in accordance with the terms hereof
or thereof. All consents, authorizations, permits, orders, filings and
registrations which the Company is required to obtain pursuant to the preceding
sentence have been obtained or effected on or prior to the date hereof and are
in full force and effect as of the date hereof. The Company is not in violation
of the listing requirements of the Principal Market as in effect on the date
hereof and on each of the Closing Dates and is not aware of any facts which
would reasonably lead to delisting of the Common Stock by the Principal Market
in the foreseeable future.

(f)  SEC Documents; Financial Statements.  Since at least May 17, 2004, the
Company has filed all reports, schedules, forms, statements and other documents
required to be filed by it with the SEC pursuant to the reporting requirements
of the 1934 Act (all of the foregoing filed prior to the date hereof and all
exhibits included therein and financial statements and schedules thereto and
documents incorporated by reference therein being hereinafter referred to as the
"SEC Documents"). The Company has delivered to the Investor or its
representatives, or they have had access through EDGAR to, true and complete
copies of the SEC Documents. As of their respective dates, the SEC Documents
complied in all material respects with the requirements of the 1934 Act and the
rules and regulations of the SEC promulgated thereunder applicable to the SEC
Documents, and none of the SEC Documents, at the time they were filed with the
SEC, contained any untrue statement of a material fact or omitted to state a
material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not
misleading. As of their respective filing dates, the financial statements of the
Company included in the SEC Documents complied as to form in all material
respects with applicable accounting requirements and the published rules and
regulations of the SEC with respect thereto. Such financial statements have been
prepared in accordance with generally accepted accounting principles,
consistently applied, during the periods involved (except (i) as may be
otherwise indicated in such financial statements or the notes thereto, or (ii)
in the case of unaudited interim statements, to the extent they may exclude
footnotes or may be condensed or summary statements) and fairly present in all
material respects the financial position of the Company as of the dates thereof
and the results of its operations and cash flows for the periods then ended
(subject, in the case of unaudited statements, to normal year-end audit
adjustments). No other written information provided by or on behalf of the
Company to the Investor which is not included in the SEC Documents contains any
untrue statement of a material fact or omits to state any material fact
necessary to make the statements therein, in the light of the circumstance under
which they are or were made, not misleading. Neither the Company nor any of its
Subsidiaries or any of their officers, directors, employees or agents have
provided the Investor with any material, nonpublic information which was not
publicly disclosed prior to the date hereof and any material, nonpublic
information provided to the Investor by the Company or its Subsidiaries or any
of their officers, directors, employees or agents prior to any Closing Date
shall be publicly disclosed by the Company prior to such Closing Date.

(g)  Absence of Certain Changes.  Except as set forth in the Schedules hereto or
the SEC Documents, the Company does not currently intend to change the business
operations of the Company.  The Company has not taken any steps, and does not
currently expect to take any steps, to seek protection pursuant to any
bankruptcy law nor does the Company or its Subsidiaries have any knowledge or
reason to believe that its creditors intend to initiate involuntary bankruptcy
proceedings.

(h)  Absence of Litigation.  Except as set forth in the Schedules hereto or the
SEC Documents, there is no action, suit, proceeding, inquiry or investigation
before or by any court, public board, government agency, self-regulatory
organization or body pending or, to the knowledge of the executive officers of
Company or any of its Subsidiaries, threatened against or affecting the Company,
the Common Stock or any of the Company's Subsidiaries or any of the Company's or
the Company's Subsidiaries' officers or directors in their capacities as such,
in which an adverse decision could have a Material Adverse Effect.

(i)  Acknowledgment Regarding Investor's Purchase of Shares.  The Company
acknowledges and agrees that the Investor is acting solely in the capacity of
arm's length purchaser with respect to the Transaction Documents and the
transactions contemplated hereby and thereby. The Company further acknowledges
that the Investor is not acting as a financial advisor or fiduciary of the
Company (or in any similar capacity) with respect to the Transaction Documents
and the transactions contemplated hereby and thereby and any advice given by the
Investor or any of its respective representatives or agents in connection with
the Transaction Documents and the transactions contemplated hereby and thereby
is merely incidental to the Investor's purchase of the Securities. The Company
further represents to the Investor that the Company's decision to enter into the
Transaction Documents has been based solely on the independent evaluation by the
Company and its representatives.

(j) No Undisclosed Events, Liabilities, Developments or Circumstances.  Except
as set forth in the SEC Documents, since March 31, 2004, no material event,
liability or development has occurred or exists, or to the Company's knowledge
is contemplated to occur, with respect to the Company or its Subsidiaries or
their respective business, properties, assets, prospects, operations or
financial condition, that would be required to be disclosed by the Company under
applicable securities laws on a registration statement filed with the SEC
relating to an issuance and sale by the Company of its Common Stock and which
has not been publicly announced.

(k) Employee Relations.  Neither the Company nor any of its Subsidiaries is
involved in any union labor dispute nor, to the knowledge of the Company or any
of its Subsidiaries, is any such dispute threatened. Neither the Company nor any
of its Subsidiaries is a party to a collective bargaining agreement, and the
Company and its Subsidiaries believe that relations with their employees are
good. No executive officer (as defined in Rule 501(f) of the 1933 Act) has
notified the Company that such officer intends to leave the Company's employ or
otherwise terminate such officer's employment with the Company.

(l)  Intellectual Property Rights.  The Company and its Subsidiaries own or
possess adequate rights or licenses to use all trademarks, trade names, service
marks, service mark registrations, service names, patents, patent rights,
copyrights, inventions, licenses, approvals, governmental authorizations, trade
secrets and rights necessary to conduct their respective businesses as now
conducted. Except as set forth in the Schedules hereto or the SEC Documents,
none of the Company's trademarks, trade names, service marks, service mark
registrations, service names, patents, patent rights, copyrights, inventions,
licenses, approvals, government authorizations, trade secrets or other
intellectual property rights necessary to conduct its business as now or as
proposed to be conducted have expired or terminated, or are expected to expire
or terminate within two years from the date of this Agreement. The Company and
its Subsidiaries do not have any knowledge of any infringement by the Company or
its Subsidiaries of trademark, trade name rights, patents, patent rights,
copyrights, inventions, licenses, service names, service marks, service mark
registrations, trade secret or other similar rights of others, and, except as
set forth on the SEC Documents, there is no claim, action or proceeding being
made or brought against, or to the Company's knowledge, being threatened
against, the Company or its Subsidiaries regarding trademark, trade name,
patents, patent rights, invention, copyright, license, service names, service
marks, service mark registrations, trade secret or other infringement; and the
Company and its Subsidiaries are unaware of any facts or circumstances which
might give rise to any of the foregoing. The Company and its Subsidiaries have
taken commercially reasonable security measures to protect the secrecy,
confidentiality and value of all of their intellectual properties.

(m)  Environmental Laws.  The Company and its Subsidiaries (i) are, to the
knowledge of management of the Company, in compliance with any and all
applicable foreign, federal, state and local laws and regulations relating to
the protection of human health and safety, the environment or hazardous or toxic
substances or wastes, pollutants or contaminants ("Environmental Laws"); (ii)
have, to the knowledge of management of the Company, received all permits,
licenses or other approvals required of them under applicable Environmental Laws
to conduct their respective businesses; and (iii) are in compliance, to the
knowledge of the Company, with all terms and conditions of any such permit,
license or approval where, in each of the three foregoing cases, the failure to
so comply would have, individually or in the aggregate, a Material Adverse
Effect.

(n)  Title.  The Company and its Subsidiaries have good and marketable title in
fee simple to all real property and good and marketable title to all personal
property owned by them which is material to the business of the Company and its
Subsidiaries, in each case free and clear of all liens, encumbrances and defects
except such as are described in the SEC Documents or such as do not materially
affect the value of such property and do not interfere with the use made and
proposed to be made of such property by the Company or any of its Subsidiaries.
Any real property and facilities held under lease by the Company or any of its
Subsidiaries are held by them under valid, subsisting and enforceable leases
with such exceptions as are not material and do not interfere with the use made
and proposed to be made of such property and buildings by the Company and its
Subsidiaries.

(o)  Insurance.  The Company and each of its Subsidiaries are insured by
insurers of recognized financial responsibility against such losses and risks
and in such amounts as management of the Company reasonably believes to be
prudent and customary in the businesses in which the Company and its
Subsidiaries are engaged. Neither the Company nor any such Subsidiary has been
refused any insurance coverage sought or applied for and neither the Company nor
any such Subsidiary has any reason to believe that it will not be able to renew
its existing insurance coverage as and when such coverage expires or to obtain
similar coverage from similar insurers as may be necessary to continue its
business at a cost that would not have a Material Adverse Effect.

(p)  Regulatory Permits.  The Company and its Subsidiaries have in full force
and effect all certificates, approvals, authorizations and permits from the
appropriate federal, state, local or foreign regulatory authorities and
comparable foreign regulatory agencies, necessary to own, lease or operate their
respective properties and assets and conduct their respective businesses, and
neither the Company nor any such Subsidiary has received any notice of
proceedings relating to the revocation or modification of any such certificate,
approval, authorization or permit, except for such certificates, approvals,
authorizations or permits which if not obtained, or such revocations or
modifications which, would not have a Material Adverse Effect.

(q)  Internal Accounting Controls.  The Company and each of its Subsidiaries
maintain a system of internal accounting controls sufficient to provide
reasonable assurance that (i) transactions are executed in accordance with
management's general or specific authorizations; (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with
generally accepted accounting principles and to maintain asset accountability;
(iii) access to assets is permitted only in accordance with management's general
or specific authorization; and (iv) the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate action
is taken with respect to any differences.

(r)  No Materially Adverse Contracts, Etc.  Neither the Company nor any of its
Subsidiaries is subject to any charter, corporate or other legal restriction, or
any judgment, decree, order, rule or regulation which in the judgment of the
Company's executive officers has or is reasonably expected in the future to have
a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is a
party to any contract or agreement which in the judgment of the Company's
executive officers has or is reasonably expected to have a Material Adverse
Effect.

(s)  Tax Status.  The Company and each of its Subsidiaries has made or filed all
United States federal and state income and all other tax returns, reports and
declarations required by any jurisdiction to which it is subject (unless and
only to the extent that the Company and each of its Subsidiaries has set aside
on its books provisions reasonably adequate for the payment of all unpaid and
unreported taxes) and has paid all taxes and other governmental assessments and
charges that are material in amount, shown or determined to be due on such
returns, reports and declarations, except those being contested in good faith
and has set aside on its books provision reasonably adequate for the payment of
all taxes for periods subsequent to the periods to which such returns, reports
or declarations apply. There are no unpaid taxes in any material amount claimed
to be due by the taxing authority of any jurisdiction, and the executive
officers of the Company know of no basis for any such claim.

(t)  Certain Transactions.  Except as set forth in the SEC Documents filed at
least ten days prior to the date hereof and except for arm's length transactions
pursuant to which the Company makes payments in the ordinary course of business
upon terms no less favorable than the Company could obtain from third parties
and other than the grant of stock options disclosed in the SEC Documents, none
of the officers, directors, or employees of the Company is presently a party to
any transaction with the Company or any of its Subsidiaries (other than for
services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or
by, providing for rental of real or personal property to or from, or otherwise
requiring payments to or from any officer, director or such employee or, to the
knowledge of the Company, any corporation, partnership, trust or other entity in
which any officer, director, or any such employee has a substantial interest or
is an officer, director, trustee or partner.

(u)  Dilutive Effect.  The Company understands and acknowledges that the number
of Shares issuable upon purchases pursuant to this Agreement will increase in
certain circumstances including, but not necessarily limited to, the
circumstance wherein the trading price of the Common Stock declines during the
period between the Effective Date and the end of the Open Period.  The Company's
executive officers and directors have studied and fully understand the nature of
the transactions contemplated by this Agreement and recognize that they have a
potential dilutive effect.  The Board of Directors of the Company has concluded,
in its good faith business judgment, that such issuance is in the best interests
of the Company.  The Company specifically acknowledges that, subject to such
limitations as are expressly set forth in the Transaction Documents, its
obligation to issue Shares of Common Stock upon purchases pursuant to this
Agreement is absolute and unconditional regardless of the dilutive effect that
such issuance may have on the ownership interests of other shareholders of the
Company.

(v)   Right of First Refusal. The Company shall not, directly or indirectly,
without the prior written consent of Investor offer, sell, grant any option to
purchase, or otherwise dispose of (or announce any offer, sale, grant or any
option to purchase or other disposition) any of its Common Stock or securities
convertible into Common Stock at a price that is less than the market price of
the Common Stock at the time of issuance of such security or investment (a
"Subsequent Financing") for a period of one year after the Effective Date,
except (i) the granting of options or warrants to employees, officers, directors
and consultants, and the issuance of Shares upon exercise of options granted,
under any stock option plan heretofore or hereafter duly adopted by the Company
or for services rendered or to be rendered; (ii) Shares issued upon exercise of
any currently outstanding warrants or options and upon conversion of any
currently outstanding convertible debenture or convertible preferred stock, in
each case disclosed pursuant to Section 4(c); (iii) securities issued in
connection with the capitalization or creation of a joint venture with a
strategic partner; (iv) securities issued to pay part or all of the purchase
price for the acquisition by the Company of another entity (which, for purposes
of this clause (iv), shall not include an individual or group of individuals);
and (v) securities issued in a bona fide public offering by the Company of its
securities, unless (A) the Company delivers to Investor a written notice (the
"Subsequent Financing Notice") of its intention to effect such Subsequent
Financing, which Subsequent Financing Notice shall describe in reasonable detail
the proposed terms of such Subsequent Financing, the amount of proceeds intended
to be raised thereunder, the person with whom such Subsequent Financing shall be
effected, and attached to which shall be a term sheet or similar document
relating thereto; and (B) Investor shall not have notified the Company by 5:00
p.m. (New York time) on the fifth Trading Day after its receipt of the
Subsequent Financing Notice of its willingness to provide, subject to completion
of mutually acceptable documentation, financing to the Company on the same terms
set forth in the Subsequent Financing Notice. If Investor shall fail to notify
the Company of its intention to provide such financing within such time period,
then the Company may effect the Subsequent Financing substantially upon the
terms set forth in the Subsequent Financing Notice; provided that the Company
shall provide Investor with a second Subsequent Financing Notice, and Investor
shall again have the right of first refusal set forth above in this Section, if
the Subsequent Financing subject to the initial Subsequent Financing Notice
shall not have been consummated for any reason on the terms set forth in such
Subsequent Financing Notice within thirty Trading Days after the date of the
initial Subsequent Financing Notice. The rights granted to Investor in this
Section are not subject to any prior right of first refusal given to any other
person disclosed on Schedule 4(c).

(w)  Lock-up.  The Company shall cause its officers, insiders, directors,
affiliates or other related parties to refrain from selling Common Stock during
each Pricing Period, except those shares which have been previously registered
and are deemed free trading or those that have been filed or contemplated to be
filed under Rule 144 prior to the date in the preamble of this Agreement and
have yet to be sold.

(x)  No General Solicitation.  Neither the Company, nor any of its affiliates,
nor any person acting on its behalf, has engaged in any form of general
solicitation or general advertising (within the meaning of Regulation D) in
connection with the offer or sale of the Common Stock offered hereby.

        (y)  No brokers, finders or financial advisory fees or commissions will
        be payable by the Company with respect to the transaction contemplated
        by this Agreement other than described in Section 12 (m) of this
        Agreement.

Section 5.  COVENANTS OF THE COMPANY

(a)  Best Efforts.  The Company shall use commercially reasonable efforts to
timely satisfy each of the conditions to be satisfied by it as provided in
Section 7 of this Agreement.

(b)  Blue Sky.  The Company shall, at its sole cost and expense, on or before
each of the Closing Dates, take such action as the Company shall reasonably
determine is necessary to qualify the Shares for, or obtain exemption for the
Shares for, sale to the Investor at each of the Closings pursuant to this
Agreement under applicable securities or "Blue Sky" laws of such states of the
United States, as reasonably specified by Investor, and shall provide evidence
of any such action so taken to the Investor on or prior to the Closing Date.

(c)  Reporting Status.  Until the earlier to occur of (i) the first date which
is after the date this Agreement is terminated pursuant to Section 9 and on
which the Holders (as that term is defined in the Registration Rights Agreement)
may sell all of the Shares without restriction pursuant to Rule 144(k)
promulgated under the 1933 Act (or successor thereto); and (ii) the date on
which (A) the Holders shall have sold all the Shares; and (B) this Agreement has
been terminated pursuant to Section 9 (the "Registration Period"), the Company
shall file all reports required to be filed with the SEC pursuant to the 1934
Act, and the Company shall not terminate its status as a reporting company under
the 1934 Act.

(d)  Use of Proceeds.  The Company will use the proceeds from the sale of the
Shares (excluding amounts paid by the Company for fees as set forth in the
Transaction Documents) for general corporate and working capital purposes or for
other purposes deemed fit by the Company's Board of Directors.

(e)  Financial Information.  The Company agrees to make available to the
Investor via EDGAR or other electronic means the following to the Investor
during the Registration Period: (i) within five (5) Trading Days after the
filing thereof with the SEC, a copy of its Annual Reports on Form 10-KSB, its
Quarterly Reports on Form 10-QSB, any Current Reports on Form 8-K and any
Registration Statements or amendments filed pursuant to the 1933 Act; (ii) on
the same day as the release thereof, facsimile copies of all press releases
issued by the Company or any of its Subsidiaries; (iii) copies of any notices
and other information made available or given to the shareholders of the Company
generally, contemporaneously with the making available or giving thereof to the
shareholders; and (iv) within two (2) calendar days of filing or delivery
thereof, copies of all documents filed with, and all correspondence sent to, the
Principal Market, any securities exchange or market, or the National Association
of Securities Dealers, Inc., unless such information is material nonpublic
information.

(f)  Reservation of Shares.  Subject to the following sentence, the Company
shall take all action necessary to at all times have authorized, and reserved
for the purpose of issuance, a sufficient number of shares of Common Stock to
provide for the issuance of the Shares hereunder. In the event that the Company
determines that it does not have a sufficient number of authorized Shares to
reserve and keep available for issuance as described in this Section 5(f), the
Company shall use its best efforts to increase the number of authorized Shares
by seeking shareholder approval for the authorization of such additional shares.

(g)  Listing.  The Company shall promptly secure and maintain the listing of all
of the Registrable Securities (as defined in the Registration Rights Agreement)
upon the Principal Market and each other national securities exchange and
automated quotation system, if any, upon which shares of Common Stock are then
listed (subject to official notice of issuance) and shall maintain, such listing
of all Registrable Securities from time to time issuable under the terms of the
Transaction Documents. The Company shall maintain the Common Stock's
authorization for quotation on the Principal Market. Neither the Company nor any
of its Subsidiaries shall take any action which would be reasonably expected to
result in the delisting or suspension of the Common Stock on the Principal
Market (excluding suspensions of not more than one trading day resulting from
business announcements by the Company). The Company shall promptly provide to
the Investor copies of any notices it receives from the Principal Market
regarding the continued eligibility of the Common Stock for listing on such
automated quotation system or securities exchange. The Company shall pay all
fees and expenses in connection with satisfying its obligations under this
Section 5(g).

(h)  Transactions With Affiliates.  The Company shall not, and shall cause each
of its Subsidiaries not to, enter into, amend, modify or supplement, or permit
any Subsidiary to enter into, amend, modify or supplement, any agreement,
transaction, commitment or arrangement with any of its or any Subsidiary's
officers, directors, persons who were officers or directors at any time during
the previous two (2) years, shareholders who beneficially own five percent (5%)
or more of the Common Stock, or affiliates or with any individual related by
blood, marriage or adoption to any such individual or with any entity in which
any such entity or individual owns a five percent (5%) or more beneficial
interest (each a "Related Party"), except for (i) customary employment
arrangements and benefit programs on reasonable terms, (ii) any agreement,
transaction, commitment or arrangement on an arms-length basis on terms no less
favorable than terms which would have been obtainable from a person other than
such Related Party, or (iii) any agreement, transaction, commitment or
arrangement which is approved by a majority of the disinterested directors of
the Company. For purposes hereof, any director who is also an officer of the
Company or any Subsidiary of the Company shall not be a disinterested director
with respect to any such agreement, transaction, commitment or arrangement.
"Affiliate" for purposes hereof means, with respect to any person or entity,
another person or entity that, directly or indirectly, (i) has a five percent
(5%) or more equity interest in that person or entity, (ii) has five percent
(5%) or more common ownership with that person or entity, (iii) controls that
person or entity, or (iv) is under common control with that person or entity.
"Control" or "Controls" for purposes hereof means that a person or entity has
the power, direct or indirect, to conduct or govern the policies of another
person or entity.

(i)  Filing of Form 8-K.  On or before the date which is three Trading Days
after the Execution Date, the Company shall file a Current Report on Form 8-K
with the SEC describing the terms of the transaction contemplated by the
Transaction Documents in the form required by the 1934 Act, if such filing is
required.

(j)  Corporate Existence.  The Company shall use its best efforts to preserve
and continue the corporate existence of the Company.

(k)  Notice of Certain Events Affecting Registration; Suspension of Right to
Make a Put. The Company shall promptly notify Investor upon the occurrence of
any of the following events in respect of a Registration Statement or related
prospectus in respect of an offering of the Securities and shall not deliver any
Put Notice during the continuation of any of the following events: (i) receipt
of any request for additional information by the SEC or any other federal or
state governmental authority during the period of effectiveness of the
Registration Statement for amendments or supplements to the Registration
Statement or related prospectus; (ii) the issuance by the SEC or any other
federal or state governmental authority of any stop order suspending the
effectiveness of any Registration Statement or the initiation of any proceedings
for that purpose; (iii) receipt of any notification with respect to the
suspension of the qualification or exemption from qualification of any of the
Securities for sale in any jurisdiction or the initiation or threatening of any
proceeding for such purpose; (iv) the happening of any event that makes any
statement made in such Registration Statement or related prospectus or any
document incorporated or deemed to be incorporated therein by reference untrue
in any material respect or that requires the making of any changes in the
Registration Statement, related prospectus or documents so that, in the case of
a Registration Statement, it will not contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein not misleading, and that in the case of
the related prospectus, it will not contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading; and (v) the Company's reasonable
determination that a post-effective amendment to the Registration Statement
would be appropriate, and the Company shall promptly make available to Investor
any such supplement or amendment to the related prospectus. The Company shall
not deliver to Investor any Put Notice during the continuation of any of the
foregoing events.

(l) Reimbursement. If (i) Investor becomes involved in any capacity in any
action, proceeding or investigation brought by any shareholder of the Company,
in connection with or as a result of the consummation of the transactions
contemplated by the Transaction Documents, or if Investor is impleaded in any
such action, proceeding or investigation by any person (other than as a result
of a breach of the Investor's representations and warranties set forth in this
Agreement); or (ii) Investor becomes involved in any capacity in any action,
proceeding or investigation brought by the SEC against or involving the Company
or in connection with or as a result of the consummation of the transactions
contemplated by the Transaction Documents (other than as a result of a breach of
the Investor's representations and warranties set forth in this Agreement), or
if Investor is impleaded in any such action, proceeding or investigation by any
person, then in any such case, the Company will reimburse Investor for its
reasonable legal and other expenses (including the cost of any investigation and
preparation) incurred in connection therewith, as such expenses are incurred. In
addition, other than with respect to any matter in which Investor is a named
party, the Company will pay to Investor the charges, as reasonably determined by
Investor, for the time of any officers or employees of Investor devoted to
appearing and preparing to appear as witnesses, assisting in preparation for
hearings, trials or pretrial matters, or otherwise with respect to inquiries,
hearing, trials, and other proceedings relating to the subject matter of this
Agreement. The reimbursement obligations of the Company under this section shall
be in addition to any liability which the Company may otherwise have, shall
extend upon the same terms and conditions to any affiliates of Investor that are
actually named in such action, proceeding or investigation, and partners,
directors, agents, employees, attorneys, accountants, auditors and controlling
persons (if any), as the case may be, of Investor and any such affiliate, and
shall be binding upon and inure to the benefit of any successors of the Company,
Investor and any such affiliate and any such person.

Section 6.  COVER.  If the number of Shares represented by any Put Notices
become restricted or are no longer freely trading for any reason, and after the
applicable Closing Date, the Investor purchases, in an open market transaction
or otherwise, the Company's Common Stock (the "Covering Shares") in order to
make delivery in satisfaction of a sale of Common Stock by the Investor (the
"Sold Shares"), which delivery such Investor anticipated to make using the
Shares represented by the Put Notice  (a "Buy In"), the Company shall pay to the
Investor the Buy In Adjustment Amount (as defined below).  The "Buy In
Adjustment Amount" is the amount equal to the excess, if any, of (a) the
Investor's total purchase price (including brokerage commissions, if any) for
the Covering Shares over (b) the net proceeds (after brokerage commissions, if
any) received by the Investor from the sale of the Sold Shares.  The Company
shall pay the Buy In Adjustment Amount to the Investor in immediately available
funds immediately upon demand by the Investor.  By way of illustration and not
in limitation of the foregoing, if the Investor purchases Common Stock having a
total purchase price (including brokerage commissions) of $11,000 to cover a Buy
In with respect to the Common Stock it sold for net proceeds of $10,000, the Buy
In Adjustment Amount which the Company will be required to pay to the Investor
will be $1,000.


Section 7.  CONDITIONS OF THE COMPANY'S OBLIGATION TO SELL.

 The obligation hereunder of the Company to issue and sell the Shares to the
 Investor is further subject to the satisfaction, at or before each Closing
 Date, of each of the following conditions set forth below. These conditions are
 for the Company's sole benefit and may be waived by the Company at any time in
 its sole discretion.

 (a)  The Investor shall have executed each of this Agreement and the
 Registration Rights Agreement and delivered the same to the Company.

 (b)  The Investor shall have delivered to the Company the Purchase Price for
 the Shares being purchased by the Investor at the Closing (after receipt of
 confirmation of delivery of such Shares) by wire transfer of immediately
 available funds pursuant to the wire instructions provided by the Company.

 (c)  No statute, rule, regulation, executive order, decree, ruling or
 injunction shall have been enacted, entered, promulgated or endorsed by any
 court or governmental authority of competent jurisdiction which prohibits the
 consummation of any of the transactions contemplated by this Agreement.

Section 8.  FURTHER CONDITIONS OF THE INVESTOR'S OBLIGATION TO PURCHASE.

The obligation of the Investor hereunder to purchase Shares is subject to the
satisfaction, on or before each Closing Date, of each of the following
conditions set forth below.

(a)  The Company shall have executed each of the Transaction Documents and
delivered the same to the Investor.

(b) The Common Stock shall be authorized for quotation on the Principal Market
and trading in the Common Stock shall not have been suspended by the Principal
Market or the SEC, at any time beginning on the date hereof and through and
including the respective Closing Date (excluding suspensions of not more than
one Trading Day resulting from business announcements by the Company, provided
that such suspensions occur prior to the Company's delivery of the Put Notice
related to such Closing).

(c)  The representations and warranties of the Company shall be true and correct
as of the date when made and as of the applicable Closing Date as though made at
that time (except for (i) representations and warranties that speak as of a
specific date and (ii) with respect to the representations made in Sections
4(g), (h) and (j) and the third sentence of Section 4(k) hereof, events which
occur on or after the date of this Agreement and are disclosed in SEC filings
made by the Company at least ten Trading Days prior to the applicable Put Notice
Date) and the Company shall have performed, satisfied and complied with the
covenants, agreements and conditions required by the Transaction Documents to be
performed, satisfied or complied with by the Company on or before such Closing
Date.  The Investor may request an update as of such Closing Date regarding the
representation contained in Section 4(c) above.

(d)   The Company shall have executed and delivered to the Investor the
certificates representing, or have executed electronic book-entry transfer of,
the Shares (in such denominations as such Investor shall request) being
purchased by the Investor at such Closing.

(e)  The Board of Directors of the Company shall have adopted resolutions
consistent with Section 4(b)(ii) above (the "Resolutions") and such Resolutions
shall not have been amended or rescinded prior to such Closing Date.

(f)  reserved.

(g)  No statute, rule, regulation, executive order, decree, ruling or injunction
shall have been enacted, entered, promulgated or endorsed by any court or
governmental authority of competent jurisdiction which prohibits the
consummation of any of the transactions contemplated by this Agreement.

(h) The Registration Statement shall be effective on each Closing Date and no
stop order suspending the effectiveness of the Registration Statement shall be
in effect or shall be pending or threatened. Furthermore, on each Closing Date
(i) neither the Company nor Investor shall have received notice that the SEC has
issued or intends to issue a stop order with respect to such Registration
Statement or that the SEC otherwise has suspended or withdrawn the effectiveness
of such Registration Statement, either temporarily or permanently, or intends or
has threatened to do so (unless the SEC's concerns have been addressed and
Investor is reasonably satisfied that the SEC no longer is considering or
intends to take such action), and (ii) no other suspension of the use or
withdrawal of the effectiveness of such Registration Statement or related
prospectus shall exist.

(i)  At the time of each Closing, the Registration Statement (including
information or documents incorporated by reference therein) and any amendments
or supplements thereto shall not contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary to
make the statements therein not misleading or which would require public
disclosure or an update supplement to the prospectus.

(j)  If applicable, the shareholders of the Company shall have approved the
issuance of any Shares in excess of the Maximum Common Stock Issuance in
accordance with Section 2(i).

(k)  The conditions to such Closing set forth in Section 2(f) shall have been
satisfied on or before such Closing Date.

(l)  The Company shall have certified to the Investor the number of Shares of
Common Stock outstanding when a Put Notice is given to the Investor.

Section 9.  TERMINATION.  This Agreement shall terminate upon any of the
following events:

(i) when the Investor has purchased an aggregate of Five Million Dollars
($5,000,000) in the Common Stock of the Company pursuant to this Agreement;
provided that the Company's representations, warranties and covenants contained
in this Agreement insofar as applicable to the transactions consummated
hereunder prior to such termination, shall survive the termination of this
Agreement for a period of one year; or

(ii)  on the date which is thirty-six (36) months after the Effective Date;

Section 10.  SUSPENSION. This Agreement shall be suspended upon any of the
following events, and shall remain suspended until such event is rectified:

(i)  the trading of the Common Stock is suspended by the SEC, the Principal
Market or the NASD for a period of five consecutive Trading Days during the Open
Period; or

(ii)  The Common Stock ceases to be registered under the 1934 Act or listed or
traded on the Principal Market.  Upon the occurrence of one of the above-
described events, the Company shall send written notice of such event to the
Investor.

Section 11.  INDEMNIFICATION.  In consideration of the parties mutual
obligations set forth in the Transaction Documents, each of the parties (in such
capacity, an "Indemnitor") shall defend, protect, indemnify and hold harmless
the the other and all of the other party's shareholders, officers, directors,
employees, counsel, and any of the foregoing person's agents or other
representatives (including, without limitation, those retained in connection
with the transactions contemplated by this Agreement) (collectively, the
"Indemnitees") from and against any and all actions, causes of action, suits,
claims, losses, costs, penalties, fees, liabilities and damages, and expenses in
connection therewith (irrespective of whether any such Indemnitee is a party to
the action for which indemnification hereunder is sought), and including
reasonable attorneys' fees and disbursements (the "Indemnified Liabilities"),
incurred by any Indemnitee as a result of, or arising out of, or relating to (i)
any misrepresentation or breach of any representation or warranty made by the
Indemnitor or any other certificate, instrument or document contemplated hereby
or thereby; (ii) any breach of any covenant, agreement or obligation of the
Indemnitor contained in the Transaction Documents or any other certificate,
instrument or document  contemplated hereby or thereby; or (iii) any cause of
action, suit or claim brought or made against such Indemnitee by a third party
and arising out of or resulting from the execution, delivery, performance or
enforcement of the Transaction Documents or any other certificate, instrument or
document contemplated hereby or thereby, except insofar as any such
misrepresentation, breach or any untrue statement, alleged untrue statement,
omission or alleged omission is made in reliance upon and in conformity with
written information furnished to Indemnitor which is specifically intended for
use in the preparation of any such Registration Statement, preliminary
prospectus, prospectus or amendments to the prospectus. To the extent that the
foregoing undertaking by the Indenitor may be unenforceable for any reason, the
Indemnitor shall make the maximum contribution to the payment and satisfaction
of each of the Indemnified Liabilities which is permissible under applicable
law. The indemnity provisions contained herein shall be in addition to any cause
of action or similar rights Indemnitor may have, and any liabilities the
Indemnitor or the Indemnitees may be subject to.

Section 12.  GOVERNING LAW; MISCELLANEOUS.

(a) Governing Law. This Agreement shall be governed by and interpreted in
accordance with the laws of the Commonwealth of Massachusetts without regard to
the principles of conflict of laws. Each party hereby irrevocably submits to the
exclusive jurisdiction of the state and federal courts sitting in the City of
Boston, County of Suffolk, for the adjudication of any dispute hereunder or in
connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit,
action or proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such suit, action or proceeding is brought
in an inconvenient forum or that the venue of such suit, action or proceeding is
improper. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such suit, action or proceeding by
mailing a copy thereof to such party at the address for such notices to it under
this Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law.
If any provision of this Agreement shall be invalid or unenforceable in any
jurisdiction, such invalidity or unenforceability shall not affect the validity
or enforceability of the remainder of this Agreement in that jurisdiction or the
validity or enforceability of any provision of this Agreement in any other
jurisdiction.

(b)  Legal Fees; and Miscellaneous Fees.  Except as otherwise set forth in the
Transaction Documents, the Company shall pay the fees and expenses of its
advisers, counsel, the accountants and other experts, if any, and all other
expenses incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of this Agreement. Any attorneys' fees and
expenses incurred by either the Company or by the Investor in connection with
the preparation, negotiation, execution and delivery of any amendments to this
Agreement or relating to the enforcement of the rights of any party, after the
occurrence of any breach of the terms of this Agreement by another party or any
default by another party in respect of the transactions contemplated hereunder,
shall be paid on demand by the party which breached the Agreement and/or
defaulted, as the case may be. The Company shall pay all stamp and other taxes
and duties levied in connection with the issuance of any Securities.

(c)  Counterparts. This Agreement may be executed in two (2) or more identical
counterparts, all of which shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and
delivered to the other party; provided that a facsimile signature shall be
considered due execution and shall be binding upon the signatory thereto with
the same force and effect as if the signature were an original, not a facsimile
signature.

(d)  Headings; Singular/Plural. The headings of this Agreement are for
convenience of reference and shall not form part of, or affect the
interpretation of, this Agreement.  Whenever required by the context of this
Agreement, the singular shall include the plural and masculine shall include the
feminine.

(e)  Severability. If any provision of this Agreement shall be invalid or
unenforceable in any jurisdiction, such invalidity or unenforceability shall not
affect the validity or enforceability of the remainder of this Agreement in that
jurisdiction or the validity or enforceability of any provision of this
Agreement in any other jurisdiction.

(f)  Entire Agreement; Amendments. This Agreement supersedes all other prior
oral or written agreements between the Investor, the Company, their affiliates
and persons acting on their behalf with respect to the matters discussed herein,
and this Agreement and the instruments referenced herein (including the other
Transaction Documents) contain the entire understanding of the parties with
respect to the matters covered herein and therein and, except as specifically
set forth herein or therein, neither the Company nor the Investor makes any
representation, warranty, covenant or undertaking with respect to such matters.
No provision of this Agreement may be amended other than by an instrument in
writing signed by the Company and the Investor, and no provision hereof may be
waived other than by an instrument in writing signed by the party against whom
enforcement is sought.

(g)  Notices. Any notices or other communications required or permitted to be
given under the terms of this Agreement must be in writing and will be deemed to
have been delivered (i) upon receipt, when delivered personally; (ii) upon
receipt, when sent by facsimile (provided confirmation of transmission is
mechanically or electronically generated and kept on file by the sending party);
or (iii) one (1) day after deposit with a nationally recognized overnight
delivery service, in each case properly addressed to the party to receive the
same. The addresses and facsimile numbers for such communications shall be:

        If to the Company:

Human BioSystems
1127 Harker Avenue
Palo Alto, California  94301
Telephone:      650-323-0943
Facsimile:      650-327-8658

If to the Investor:

                Dutchess Private Equities Fund, II, LP
                312 Stuart Street
                Boston, MA  02116
                Telephone:      617-960-3582
                Facsimile:      617-960-3772

Each party shall provide five days' prior written notice to the other party of
any change in address or facsimile number.

(h)  No Assignment. This Agreement may not be assigned.

(i)  No Third Party Beneficiaries. This Agreement is intended for the benefit of
the parties hereto and is not for the benefit of, nor may any provision hereof
be enforced by, any other person.

(j)  Survival. The representations and warranties of the Company and the
Investor contained in Sections 2 and 3, the agreements and covenants set forth
in Sections 4 and 5, and the indemnification provisions set forth in Section 11,
shall survive each of the Closings and the termination of this Agreement.

(k)  Publicity.  The Company and Investor shall consult with each other in
issuing any press releases or otherwise making public statements with respect to
the transactions contemplated hereby and no party shall issue any such press
release or otherwise make any such public statement without the prior written
consent of the other parties, which consent shall not be unreasonably withheld
or delayed, except that no prior consent shall be required if such disclosure is
required by law, in which such case the disclosing party shall provide the other
parties with prior notice of such public statement. Notwithstanding the
foregoing, the Company shall not publicly disclose the name of Investor without
the prior written consent of such Investor, except to the extent required by
law. Investor acknowledges that this Agreement and all or part of the
Transaction Documents may be deemed to be "material contracts" as that term is
defined by Item 601(b)(10) of Regulation S-B, and that the Company may therefore
be required to file such documents as exhibits to reports or registration
statements filed under the 1933 Act or the 1934 Act. Investor further agrees
that the status of such documents and materials as material contracts shall be
determined  solely by the Company, in consultation with its counsel.

(l)  Further Assurances. Each party shall do and perform, or cause to be done
and performed, all such further acts and things, and shall execute and deliver
all such other agreements, certificates, instruments and documents, as the other
party may reasonably request in order to carry out the intent and accomplish the
purposes of this Agreement and the consummation of the transactions contemplated
hereby.

(m)  Placement Agent. The Company agrees to pay _________________, ("_____") a
registered broker dealer, $10,000.  The $10,000 shall be payable from 1% (one
percent) of the Put Amount on each draw toward the fee.   ________will also act
as an unaffiliated broker dealer.  The Investor shall have no obligation with
respect to any fees or with respect to any claims made by or on behalf of other
persons or entities for fees of a type contemplated in this Section that may be
due in connection with the transactions contemplated by the Transaction
Documents.  The Company shall indemnify and hold harmless the Investor, their
employees, officers, directors, agents, and partners, and their respective
affiliates, from and against all claims, losses, damages, costs (including the
costs of preparation and attorney's fees) and expenses incurred in respect of
any such claimed or existing fees, as such fees and expenses are incurred.

(n)  No Strict Construction. The language used in this Agreement will be deemed
to be the language chosen by the parties to express their mutual intent, and no
rules of strict construction will be applied against any party.

(o)  Remedies. The Investor and each holder of the Shares shall have all rights
and remedies set forth in this Agreement and the Registration Rights Agreement
and all rights and remedies which such holders have been granted at any time
under any other agreement or contract and all of the rights which such holders
have under any law. Any person having any rights under any provision of this
Agreement shall be entitled to enforce such rights specifically (without posting
a bond or other security), to recover damages by reason of any default or breach
of any provision of this Agreement, including the recovery of reasonable
attorneys fees and costs, and to exercise all other rights granted by law.

(p)  Payment Set Aside. To the extent that the Company makes a payment or
payments to the Investor hereunder or the Registration Rights Agreement or the
Investor enforces or exercises its rights hereunder or thereunder, and such
payment or payments or the proceeds of such enforcement or exercise or any part
thereof are subsequently invalidated, declared to be fraudulent or preferential,
set aside, recovered from, disgorged by or are required to be refunded, repaid
or otherwise restored to the Company, a trustee, receiver or any other person
under any law (including, without limitation, any bankruptcy law, state or
federal law, common law or equitable cause of action), then to the extent of any
such restoration the obligation or part thereof originally intended to be
satisfied shall be revived and continued in full force and effect as if such
payment had not been made or such enforcement or setoff had not occurred.

(q)  Pricing of Common Stock.  For purposes of this Agreement, the bid price of
the Common Stock in this Agreement shall be as reported on Bloomberg.com.

* * *

SIGNATURE PAGE OF INVESTMENT AGREEMENT

The signature of the authorized representative of the on this Signature Page
evidences the Company
's agreement to be bound by the terms and conditions of the
Investment Agreement and the Registration Rights Agreement as of the date first
written above.

The undersigned signatory hereby certifies that he has read and understands the
Investment Agreement, and the representations made by the Company in this
Investment Agreement are true and accurate, and on behalf of the Company, agrees
to be bound by its terms.



DUTCHESS PRIVATE EQUITIES FUND, II, L.P.
BY ITS GENERAL PARTNER,
DUTCHESS CAPITAL MANAGEMENT, LLC



By:/s/ Douglas H. Leighton
 -----------------------------------------
       Douglas H. Leighton, Managing Member



HUMAN BIOSYSTEMS,



By:/s/ Harry Masuda
-------------------------------------------
       Harry Masuda, Chief Executive Officer


LIST OF EXHIBITS
-----------------


EXHIBIT A                       Registration Rights Agreement
EXHIBIT B                       Opinion of Company's Counsel
EXHIBIT C                       [reserved]
EXHIBIT D                       Broker Representation Letter
EXHIBIT E                       Board Resolution
EXHIBIT F                       Put Notice
EXHIBIT G                       Put Settlement Sheet


LIST OF SCHEDULES
-----------------

Schedule 4(a)                 Subsidiaries
Schedule 4(c)                 Capitalization
Schedule 4(e)                 Conflicts
Schedule 4(g)                 Material Changes
Schedule 4(h)                 Litigation
Schedule 4(l)                 Intellectual Property
Schedule 4(n)                 Liens
Schedule 4(t)                 Certain Transactions




EXHIBIT A



EXHIBIT B



EXHIBIT C



EXHIBIT D

[BROKER'S LETTERHEAD]




Date
Via Facsimile

Attention:
______________________
______________________
______________________

Re: Human Biosystems

Dear __________________:

It is our understanding that the Form______ Registration Statement bearing SEC
File Number ( ___-______) filed by Human Biosystems on Form _____ on __________,
2004 was declared effective on _________, 2004.

This letter shall confirm that ______________ shares of the common stock of
Human Biosystems are being sold on behalf of __________________ and that we
shall comply with the prospectus delivery requirements set forth in that
Registration Statement by filing the same with the purchaser.

If you have any questions please do not hesitate to call.

Sincerely,



______________________



cc:  .



EXHIBIT E



EXHIBIT F

Date:

RE: Put Notice Number __

Dear Mr. Leighton,

This is to inform you that as of today, Human Biosystems, a California
corporation (the "Company"), hereby elects to exercise its right pursuant to the
Investment Agreement to require Dutchess Private Equities Fund, II, LP. to
purchase shares of its common stock.   The Company hereby certifies that:

The amount of this put is $__________.

The Pricing Period runs from ________ until _______.

The current number of shares issued and outstanding as of the Company are:

____________________

Regards,



________________________
Harry Masuda
Human Biosystems



EXHIBIT G


PUT SETTLEMENT SHEET

Date:

Harry,

Pursuant to the Put given by Human Biosystems. to Dutchess Private Equities
Fund, II, L.P. on _________________ 200x, we are now submitting the amount of
common shares for you to issue to Dutchess.

Please have a certificate baring no restrictive legend totaling __________
shares issued to Dutchess Private Equities Fund, II, LP immediately and send via
DWAC to the following account:

XXXXXX

If not DWAC eligible, please send Fedex Priority Overnight to:

XXXXXX

Once these shares are received by us, we will break have the funds wired to the
Company.

Regards,


Douglas H. Leighton


Date               Price
-----          ---------------
Date of Day 1   Closing Bid of Day 1
Date of Day 2   Closing Bid of Day 2
Date of Day 3   Closing Bid of Day 3
Date of Day 4   Closing Bid of Day 4
Date of Day 5   Closing Bid of Day 5






Lowest 1 (one) Closing Bid in Pricing Period


Put Amount

Amount Wired to Company

Purchase Price (95% (ninety-five percent))

Amount of Shares Due

The undersigned has completed this Put as of this ___th day of _________, 20xx.

Human Biosystems

________________________________
Harry Masuda, CEO


SCHEDULE 4(c)  CAPITALIZATION

SCHEDULE 4(e) CONFLICTS

SCHEDULE 4(g)  MATERIAL CHANGES

SCHEDULE 4(h)  LITIGATION

SCHEDULE 4(l)  INTELLECTUAL PROPERTY


SCHEDULE 4(n)  LIENS


SCHEDULE 4(t)  CERTAIN TRANSACTIONS